Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors

NCT07115043 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07115043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07115043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 29, 2025
Completion date
October 2, 2029
Enrollment
120 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer/gastroesophageal junction cancer, head and neck squamous cell carcinoma, high grade serous ovarian carcinoma, melanoma, merkel cell carcinoma, non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma (skin), triple negative breast cancer